Effectiveness and Safety of Antiobesity Medications in Patients With Obesity and Inflammatory Bowel Disease

被引：3

作者：

Pham, Jonathan T. ^{[1
]}

Ghusn, Wissam ^{[2
,3
]}

Acosta, Andres ^{[2
,3
]}

Loftus, Edward V. ^{[2
]}

Johnson, Amanda M. ^{[2
]}

机构：

[1] Mayo Clin, Coll Med & Sci, Dept Internal Med, Rochester, MN USA

[2] Mayo Clin, Coll Med & Sci, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA

[3] Mayo Clin, Coll Med & Sci, Precis Med Obes Program, Rochester, MN USA

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 06期

关键词：

inflammatory bowel disease; obesity; Crohn's disease; ulcerative colitis; antiobesity medications; CEREBROVASCULAR ACCIDENTS; RISK;

D O I：

10.14309/ajg.0000000000002490

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

INTRODUCTION: Limited data exist evaluating antiobesity medications (AOM) in patients with inflammatory bowel disease (IBD). METHODS: We performed a case-control study evaluating the effectiveness and safety of AOM in patients with IBD with obesity, matched to non-IBD controls. RESULTS: After 12 months, the case (n = 36) and control (n = 36) groups achieved similar percent total body weight loss of -6.9 +/- 8.3 and -8.1 +/- 7.0 (P = 0.30), respectively. Side effect profiles were similar between groups. Seven patients experienced an IBD flare, all managed medically. DISCUSSION: AOM use in patients with IBD demonstrated similar effectiveness and safety when compared with that observed in the non-IBD population.

引用

页码：1197 / 1200

页数：4

共 50 条

[31] Effectiveness and safety of probiotic preparations in clinical treatment of inflammatory bowel disease
Wasilewska, Ewa
Wroblewska, Barbara
POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2018, 72 : 159 - 174
[32] Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study
Kamat, Nagesh
Kedia, Saurabh
Ghoshal, Uday C.
Nehra, Abhimanyu
Makharia, Govind
Sood, Ajit
Midha, Vandana
Gupta, Varun
Choudhuri, Gourdas
Ahuja, Vineet
INDIAN JOURNAL OF GASTROENTEROLOGY, 2019, 38 (01) : 44 - 54
[33] Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review
Fang, Shengbo
Zhang, Sixi
Zhang, Chunyan
Wang, Libo
PEDIATRIC DRUGS, 2023, 25 (05) : 499 - 513
[34] Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study
Nagesh Kamat
Saurabh Kedia
Uday C. Ghoshal
Abhimanyu Nehra
Govind Makharia
Ajit Sood
Vandana Midha
Varun Gupta
Gourdas Choudhuri
Vineet Ahuja
Indian Journal of Gastroenterology, 2019, 38 : 44 - 54
[35] Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review
Shengbo Fang
Sixi Zhang
Chunyan Zhang
Libo Wang
Pediatric Drugs, 2023, 25 : 499 - 513
[36] Immunosuppressant medications and mortality in inflammatory bowel disease
Lewis, James D.
Gelfand, Joel M.
Troxel, Andrea B.
Forde, Kimberly A.
Newcomb, Craig
Kim, Hopiy
Margolis, David J.
Strom, Brian L.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (06): : 1428 - 1435
[37] Immunosuppressant medications and mortality in inflammatory bowel disease
Lewis, James D.
Gelfand, Joel M.
Troxel, Andrea B.
Forde, Kimberly A.
Newcomb, Craig
Kim, Hopiy
Margolis, David J.
Strom, Brian L.
GASTROENTEROLOGY, 2008, 134 (04) : A144 - A144
[38] Awareness Among Practitioners Regarding the Safety of Inflammatory Bowel Disease Medications During Pregnancy
Ali, Tauseef
Rhodes, Robert
Smith, Zachary
Madhoun, Mohammad F.
GASTROENTEROLOGY, 2013, 144 (05) : S409 - S409
[39] MANAGEMENT STRATEGIES FOR OBESITY VARY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Dave, Sonya
Srivastava, Sonali
Thorgerson, Abigail
Beniwal-Patel, Poonam
GASTROENTEROLOGY, 2023, 164 (06) : S680 - S681
[40] Obesity in the response to biological treatments in Inflammatory Bowel Disease patients
Cabrerizo Mengotti, M.
Agudo Fernandez, S.
Castano Milla, C.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1453 - I1453

← 1 2 3 4 5 →